Compare BETA & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BETA | BLCO |
|---|---|---|
| Founded | 2017 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Aerospace | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | 2025 | 2022 |
| Metric | BETA | BLCO |
|---|---|---|
| Price | $20.55 | $16.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $35.25 | $18.45 |
| AVG Volume (30 Days) | ★ 2.3M | 373.5K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $35,616,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $14.75 | $8.65 |
| Revenue Next Year | $918.13 | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 135.99 | 6.47 |
| 52 Week Low | $13.43 | $13.77 |
| 52 Week High | $36.43 | $18.92 |
| Indicator | BETA | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 44.07 |
| Support Level | $20.65 | $16.84 |
| Resistance Level | $21.40 | $17.20 |
| Average True Range (ATR) | 1.41 | 0.48 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 46.39 | 17.69 |
BETA Technologies Inc is an aerospace company. The group has developed an electric aircraft platform and propulsion systems that are positioned to transform the aviation industry forward into a new phase of growth. It designs, manufactures, and sells high-performance electric aircraft, modern electric propulsion systems, charging systems, and components. The group also invested in the underlying infrastructure of this breakthrough technology, which is critical to bringing electric aviation to life. The group has developed a differentiated presence in North America and is well-positioned to expand globally. Its products and services are Aircraft, Charge, Motor, Battery, Flight Controls, and Training. It has one operating segment: Development and Manufacturing of Electric Aircraft.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.